AI Article Synopsis

  • Adiponectin (Acrp30) is a hormone linked to metabolism and has been associated with the progression of various cancers, including glioblastomas (GBM).
  • Researchers found that GBM tumors express Acrp30 receptors (AdipoR1 and AdipoR2) in about 70% of cases, indicating potential relevance in this aggressive cancer type.
  • Treatment with Acrp30 in GBM cell lines was shown to inhibit cell growth and DNA synthesis, suggesting it may be a promising target for new cancer therapies.

Article Abstract

Adiponectin (Acrp30) is an adipocyte-secreted hormone with pleiotropic metabolic effects, whose reduced levels were related to development and progression of several malignancies. We looked at the presence of Acrp30 receptors in human glioblastomas (GBM), hypothesizing a role for Acrp30 also in this untreatable cancer. Here we demonstrate that human GBM express Acrp30 receptors (AdipoR1 and AdipoR2), which are often co-expressed in GBM samples (70% of the analyzed tumors). To investigate the effects of Acrp30 on GBM growth, we used human GBM cell lines U87-MG and U251, expressing both AdipoR1 and AdipoR2 receptors. In these cells, Acrp30 treatment inhibits DNA synthesis and cell proliferation rate, inducing arrest in G1 phase of the cell cycle. These effects were correlated to a sustained activation of ERK1/2 and Akt kinases, upon Acrp30 treatment. Our results suggest that Acrp30 may represent a novel endogenous negative regulator of GBM cell proliferation, to be evaluated for the possible development of novel pharmacological approaches.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.24582DOI Listing

Publication Analysis

Top Keywords

cell proliferation
12
acrp30
8
acrp30 receptors
8
human gbm
8
adipor1 adipor2
8
gbm cell
8
acrp30 treatment
8
gbm
6
cell
5
adiponectin novel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!